|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003289,
umls-concept:C0005516,
umls-concept:C0005821,
umls-concept:C0008976,
umls-concept:C0014257,
umls-concept:C0027051,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0074393,
umls-concept:C0205178,
umls-concept:C0332293,
umls-concept:C0344315,
umls-concept:C0441471,
umls-concept:C1522318,
umls-concept:C2265759,
umls-concept:C2911696
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2003-8-26
|
|
pubmed:abstractText |
Depression after acute coronary syndromes (ACSs) has been identified as an independent risk factor for subsequent cardiac death. Enhanced platelet activation has been hypothesized to represent 1 of the mechanisms underlying this association. Selective serotonin reuptake inhibitors (SSRIs) are known to inhibit platelet activity. Whether treatment of depressed post-ACS patients with SSRIs alters platelet function was not known. Accordingly, we serially assessed the release of established platelet/endothelial biomarkers in patients treated with sertraline vs placebo in the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
pubmed-author:CaliffRobert MRM,
pubmed-author:FinkelMitchell SMS,
pubmed-author:GaffneyMichaelM,
pubmed-author:GlassmanAlexander HAH,
pubmed-author:HarrisonWilmaW,
pubmed-author:KrishnanK Ranga RKR,
pubmed-author:MalininAlex IAI,
pubmed-author:MusselmanDominique LDL,
pubmed-author:NemeroffCharles BCB,
pubmed-author:O'ConnorChristopher MCM,
pubmed-author:SerebruanyVictor LVL,
pubmed-author:Sertraline AntiDepressant Heart Attack Randomized Trial Study Group,
pubmed-author:van ZylLouis TLT
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
26
|
|
pubmed:volume |
108
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
939-44
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12912814-Biological Markers,
pubmed-meshheading:12912814-Blood Platelets,
pubmed-meshheading:12912814-Coronary Disease,
pubmed-meshheading:12912814-Depression,
pubmed-meshheading:12912814-Endothelium, Vascular,
pubmed-meshheading:12912814-Female,
pubmed-meshheading:12912814-Humans,
pubmed-meshheading:12912814-Male,
pubmed-meshheading:12912814-Middle Aged,
pubmed-meshheading:12912814-Platelet Activation,
pubmed-meshheading:12912814-Platelet Aggregation Inhibitors,
pubmed-meshheading:12912814-Prospective Studies,
pubmed-meshheading:12912814-Risk Factors,
pubmed-meshheading:12912814-Serotonin Uptake Inhibitors,
pubmed-meshheading:12912814-Sertraline,
pubmed-meshheading:12912814-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy.
|
|
pubmed:affiliation |
Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, MD 21215, USA. Heartdrug@aol.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
